Search

Semantic interoperability for the Internet of Things (IoT) is enabled by standards and technologies from the Semantic Web. As recent research suggests a move towards decentralised IoT architectures, we have investigated the scalability and robustness of RDF (Resource Description Framework)engines that can be embedded throughout the architecture, in particular at edge nodes. RDF processing at the edge facilitates the deployment of semantic integration gateways closer to low-level devices. Our focus is on how to enable scalable and robust RDF engines that can operate on lightweight devices. In this paper, we have first carried out an empirical study of the scalability and behaviour of solutions for RDF data management on standard computing hardware that have been ported to run on lightweight devices at the network edge. The findings of our study shows that these RDF store solutions have several shortcomings on commodity ARM (Advanced RISC Machine) boards that are representative of IoT edge node hardware. Consequently, this has inspired us to introduce a lightweight RDF engine, which comprises an RDF storage and a SPARQL processor for lightweight edge devices, called RDF4Led. RDF4Led follows the RISC-style (Reduce Instruction Set Computer) design philosophy. The design constitutes a flash-aware storage structure, an indexing scheme, an alternative buffer management technique and a low-memory-footprint join algorithm that demonstrates improved scalability and robustness over competing solutions. With a significantly smaller memory footprint, we show that RDF4Led can handle 2 to 5 times more data than popular RDF engines such as Jena TDB (Tuple Database) and RDF4J, while consuming the same amount of memory. In particular, RDF4Led requires 10%–30% memory of its competitors to operate on datasets of up to 50 million triples. On memory-constrained ARM boards, it can perform faster updates and can scale better than Jena TDB and Virtuoso. Furthermore, we demonstrate considerably faster query operations than Jena TDB and RDF4J.

Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to investigate the rate of the BRAF V600E mutation, the relationships between the BRAF V600E gene mutation and some immunohistochemical markers, and recurrence rate in patients with differentiated thyroid cancer. Method: The study was conducted by a descriptive and longitudinal follow-up method on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam. All patients were identified with the BRAF V600E gene mutation by real-time polymerase chain reaction. Results: The rate of BRAF V600E gene mutation in patients with thyroid cancer was 60.8%. Patients with BRAF V600E gene mutation had a significantly higher rate of positive cyclooxygenase 2 (COX-2) and Ki67 markers than those without the mutation (COX-2: odds ratio [OR] = 2.93; 95% confidence interval [CI] = 1.27-6.74, P = .011; Ki67: OR = 3.41; 95% CI = 1.31-8.88, P = .01). A statistically significant relationship was identified between the rate of BRAF V600E mutation and the rate of positive Hector Battifora mesothelial 1 (HBME-1) (B = −1.040; P = .037) and COX-2 (B = −1.123; P = .023) markers. The recurrence rate in patients with BRAF V600E gene mutation was significantly higher than that in those without the mutation ( P = .007). The mean of the recurrence time of patients with BRAF V600E mutation was significantly lower than that in those without the mutation ( P = .011). Conclusions: A high prevalence of BRAF V600E gene mutation was found in thyroid carcinoma patients. The rates of positive HBME-1, COX-2, and Ki67 markers were significantly correlated to BRAF V600E gene mutation. Patients with BRAF V600E gene mutation showed a significantly higher relapse rate and earlier relapse time than those without the mutation.

Gnetum formosum Markgr., a member of the Gnetaceae family, is distributed in Vietnam. This plant remains a botanical enigma with an unexplored diversity of chemical constituents and pharmacological effects. In this study, two new steroidal saponins, namely gnetumosides A (1) and B (2), were isolated from the aerial parts of G. formosum. Their chemical structures were elucidated using spectroscopic techniques, including high-resolution electrospray ionization mass spectrometry (HR-ESI-MS) and NMR, along with chemical hydrolysis and comparison with the reported literature. The potential anti-inflammatory effects of the isolated compounds were evaluated by measuring lipopolysaccharide-stimulated nitric oxide (NO) production in murine macrophage cells. Notably, compound 1 exhibited the most potent inhibitory activity (IC50 = 14.10 ± 0.75 µM), comparable to dexamethasone. Additionally, the mechanisms underlying the observed anti-inflammatory effects were investigated through molecular docking and molecular dynamics simulations on inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) proteins. This study is the first to investigate the chemical constituents and pharmacological effects of G. formosum. [ABSTRACT FROM AUTHOR]

This first study investigated the presence of dioxins and furans in river sediments around a craft village in Vietnam, focusing on Secondary Steel Recycling. Sediment samples were collected from various locations along the riverbed near the Da Hoi Secondary Steel Recycling village in Bac Ninh province. The analysis was conducted using a HRGC/HRMS-DFS device, detecting a total of 17 dioxin/furan isomers in all samples, with an average total concentration of 288.86 ng/kg d.w. The concentrations of dioxin/furan congeners showed minimal variation among sediment samples, ranging from 253.9 to 344.2 ng/kg d.w. The predominant compounds in the dioxin group were OCDD, while in the furan group, they were 1,2,3,4,6,7,8-HpCDF and OCDF. The chlorine content in the molecule appeared to be closely related to the concentration of dioxins and their percentage distribution. However, the levels of furan isomers did not vary significantly. The distribution of these compounds was not dependent on the flow direction, as they were mainly found in solid waste and are not water-soluble. Although the hepta and octa congeners had high concentrations, when converted to TEQ values, the tetra and penta groups (for dioxins) and the penta and hexa groups (for furans) contributed more to toxicity. Furthermore, the source of dioxins in sediments at Da Hoi does not only originate from steel recycling production activities but also from other combustion sites. The average total toxicity was 10.92 ng TEQ/kg d.w, ranging from 4.99 to 17.88 ng TEQ/kg d.w, which did not exceed the threshold specified in QCVN 43:2017/BTNMT, the National Technical Regulation on Sediment Quality. Nonetheless, these levels are still concerning. The presence of these toxic substances not only impacts aquatic organisms in the sampled water environment but also poses potential health risks to residents living nearby. [ABSTRACT FROM AUTHOR]

Introduction: Endovascular treatment for acute ischemic stroke patients with large vessel occlusion (LVO) has been established as a promising clinical intervention within a late time window of 6–24 h after symptom onset. Patients with slow progression, however, may still benefit from endovascular treatment beyond the 24-h time window (very late window). Aim: The aim of this study is to report insight into the potential clinical benefits of endovascular treatment for acute ischemic stroke beyond 24 h from symptom onset. Methods: A retrospective analysis was performed on consecutive patients undergoing endovascular treatment for acute anterior circulation LVO ischemic stroke beyond 24 h. Participants were recruited between July 2019 and November 2020. Patients were selected based on the DAWN/DEFUSE 3 criteria (Perfusion-RAPID, iSchemaView) and patients receiving treatment beyond 24 h were compared to a group of patients receiving endovascular treatment between 6 and 24 h after symptom onset. The primary outcome was the proportion of patients with functional independence at 90 days (modified Rankin Scale score of 0–2). The secondary outcomes were shift modified Rankin Scale (mRS) analysis and successful reperfusion was defined by thrombolysis in cerebral infarction (TICI) 2b-3 on the final procedure. Safety outcomes were symptomatic intracranial hemorrhage and death at the 90-day follow-up. Propensity score (PS)-matched analyses were employed to rectify the imbalanced baseline characteristics between the two groups. Results: A total of 166 patients were recruited with a median age of 63.0 (56.0–69.0) and 28.9% of all patients were females. Patients in the beyond 24-h group had a longer onset-to-groin time (median = 27.2 vs 14.3 h, p < 0.001) than those in the 6- to 24-h group. There were no statistically significant differences between the two groups in National Institutes of Health Stroke Scale (NIHSS) (median = 12.0 vs 15.0, p = 0.37), perfusion imaging characteristics (core: median = 11.0 vs 9.0 mL, p = 0.86; mismatch volume: median = 106.0 vs 96.0, p = 0.44; mismatch ratio = 6.46 vs 7.24, p = 0.91), and perfusion-to-groin time (median = 72.5 vs 76.0 min, p = 0.77). No significant differences were noted among patients between the two groups in the primary endpoint functional independence analysis (50.0% vs 46.6%, p = 0.77) and in the safety endpoint analysis: mortality (15.0% vs 11.0%, p = 0.71) or symptomatic hemorrhage (0% vs 3.42%, p > 0.999). In PS-matched analyses, there were no significant differences among patients between the two groups in functional independence (50.0% vs 54.8%, p = 0.74), mortality (16.7% vs 9.68%, p = 0.50), or symptomatic hemorrhage (0% vs 6.45%, p = 0.53). Conclusion: Endovascular treatment can be performed safely and effectively in LVO patients beyond 24 h from symptom onset when selected by target mismatch profile. The clinical outcome of these patients was comparable to those treated in the 6- to 24-h window. Larger studies are needed to confirm these findings. [ABSTRACT FROM AUTHOR]

New derivatives of crown compounds were successfully prepared via multicomponent reactions of a thia‐podand, an β‐keto ester and ammonium acetate based on modifications of the Petrenko‐Kritschenko reaction. The structure of the synthesized compounds was identified by physical‐chemical methods of analysis including IR, NMR, HRMS, and single‐crystal X‐ray diffraction. In addition, an in vitro assay against the α‐glucosidase of synthetic compounds was first evaluated and showed positive results. The most active compound exhibited an IC50 value of 5.69±0.27 μM, which is 37 fold more potent than the standard drug of acarbose (IC50 208.42±4.68 μM). Furthermore, prediction of ADMET parameters revealed that almost all synthesized trithiacrown ether derivatives expressed drug‐like characteristics. Our results provide useful evidence that crown ether compounds are not only good chelators with metal ions but also scaffolds for developing lead candidates in the treatment of diabetic disease. [ABSTRACT FROM AUTHOR]

This study evaluated optimal locations for in situ remediation of per‐ and poly‐fluoroalkyl substances (PFAS) in groundwater with colloidal activated carbon (CAC). New Freundlich isotherms for PFAS adsorption to CAC were estimated to illustrate the effect of competitive adsorption with dissolved organic carbon and other PFAS in a groundwater sample. A hypothetical model scenario was constructed based on source area characteristics similar to a site impacted by aqueous film forming foam in South Dakota. Modeling indicates that, even with high PFAS concentrations, CAC would still be capable of maintaining concentrations below proposed maximum contaminant levels in the adsorption zone for at least 30–40 years. Two‐dimensional areal modeling indicates that the future breakthrough of PFAS is likely to occur in the localized core of the plume, and that the corresponding future reinjection of CAC will only need to be conducted over a smaller portion of the original injection footprint. The benefits of implementing a phased remedial approach at PFAS sites are discussed. Source area and mid‐plume CAC treatments are shown to be ineffective at attenuating PFAS concentrations at the downgradient property boundary within a reasonable timeframe when PFAS travel time is relatively slow. Among the CAC alternatives evaluated here, a downgradient CAC permeable reactive barrier has the best performance with respect to protecting downgradient receptors. [ABSTRACT FROM AUTHOR]

Aim: The OPTIM1SE study observed long‐term real‐world outcomes of cetuximab‐based infusional 5‐fluorouracil (5‐FU) regimens for first‐line treatment of metastatic colorectal cancer (mCRC) across Asia‐Pacific and Middle East regions, aiming to characterize their use, effectiveness, and safety in routine practice. Methods: OPTIM1SE was a prospective, open‐label, observational study. Patients with untreated KRAS wild‐type mCRC and distant metastases were treated per locally approved labels and monitored for 3 years via electronic medical records. The primary endpoint was the overall response rate (ORR). Secondary endpoints included safety, progression‐free survival (PFS), and overall survival (OS). Results: From November 19, 2013, to June 30, 2016, 520 patients were enrolled in 51 sites. Patients were mostly male (61.2%), with a mean age of 58.5 (±12.0) years; 420 patients received leucovorin, 5‐FU, and irinotecan–based regimens and 94 received leucovorin, 5‐FU, and oxaliplatin. The most common primary tumor site was the rectum (38.8%), with liver metastases (65.0%). ORR was 45.4% (95% CI, 41.1%–49.7%), including 26 patients (5.0%) with a complete response. Median PFS was 9.9 months (95% CI, 8.2–11.0); median OS (mOS) was 30.8 months (95% CI, 27.9–33.6). Higher mOS was associated with tumors of left compared with right‐sided origin (hazard ratio, 0.69 [95% CI, 0.49–0.99]); higher ORR was also associated with liver metastases compared with all other metastases (55.4% vs. 40.2%). Adverse events were consistent with the known safety profile of cetuximab. Conclusion: Cetuximab‐based 5‐FU regimens were effective first‐line treatments for mCRC in routine practice, particularly in patients with left‐sided disease and liver metastases only. [ABSTRACT FROM AUTHOR]

Background and objectives In Australia, mortality rates for hepatocellular carcinoma (HCC) are rising. Targeted surveillance is recommended to increase early diagnosis. The aim of this study was to synthesise evidence regarding HCC surveillance in primary care and identify barriers and facilitators to surveillance. Methods A systematic review was performed, with searches conducted in five biomedical databases, the Centre for Reviews and Dissemination website and the grey literature. Study quality was assessed using the National Institute for Heath and Care Excellence (NICE) quality appraisal checklists. Results In all, 32 studies, focusing on viral hepatitis and cirrhosis patients, were included in the review. HCC surveillance rates were lower for patients managed by primary care providers (PCPs) than for those managed by gastroenterologists/hepatologists. HCC surveillance rates increased when additional support was provided to PCPs (eg reminder systems, nurse follow-up). Key barriers were a lack of awareness of HCC risks and surveillance recommendations, as well as competing priorities PCPs must address when working with patients with multimorbidity. Discussion HCC surveillance programs in primary care should be accompanied by additional support for PCPs and strategies to increase awareness of clinical recommendations. [ABSTRACT FROM AUTHOR]

Targeted delivery of magnetic nanoparticles (MNPs) to an area of a blood vessel with fluidic flow is hampered by the lack of a suitable real‐time imaging modality for MNPs, the control system complexity, and low targeting performance. Herein, an offline programming guidance (OLPG) scheme for aggregated MNPs is proposed based on a real‐time aggregation volume estimator. The proposed aggregation volume estimator based on a magnetic drug‐targeting simulator reflects volume changes of aggregated MNPs; hence, it can model a magnetic force acting on aggregated MNPs in real time while enhancing targeting performance. The proposed guidance system is evaluated using a simulation testbed and in vitro model of the rat brain, which yields comparable results at different fluid viscosities, flow velocities, target areas, and flow types. The OLPG with the aggregation volume estimator improves targeting performance by 116%–409% compared with the default mode, and by 111%–180% compared to the performance without the aggregation volume estimator. Furthermore, a guidance margin predicts enhanced targeting performance (root‐mean‐square error < 5%) irrespective of the flow environment. The proposed guidance strategy has the potential to overcome the problems caused by the lack of an imaging modality, control‐system complexity, and low targeting performance. [ABSTRACT FROM AUTHOR]